Monday, November 3, 2025

STADA appoints Tomas Mihal as new Head of Germany and Member of the Global Executive Committee

STADA has appointed Tomas Mihal (45) as its new Head of Germany and member of the global STADA Executive Committee (SEC). Since November 1, 2025, Mihal has been responsible for the German business and reports directly to CEO Peter Goldschmidt.

Goldschmidt said: “We are delighted to welcome Tomas Mihal back to STADA – a passionate leader with strong international experience.” Mihal previously served as Managing Director of STADA Czech Republic from 2019, where he played a key role in the successful acquisition of the dietary supplement manufacturer Walmark.

In his new role, Mihal takes overall responsibility for STADA’s largest market by revenue and profit. His goal is to further strengthen the company’s position across the three business segments – Consumer Healthcare (CHC), Generics (ALIUD), and Specialty (STADAPHARM) – and to achieve growth that outpaces the market.

Goldschmidt emphasized: “With bold vision and entrepreneurial drive, Tomas Mihal will ensure that our German business advances its leadership ambitions across all segments.” His extensive experience will help translate strategic initiatives into measurable results for patients, partners, and the healthcare system.

Mihal added: “It is a great honor to take on responsibility for STADA’s largest market. Germany is a key growth engine with tremendous potential. I look forward to turning this potential into sustainable, long-term growth and shaping the future of healthcare together with my outstanding team.”

STADA continues to pursue a three-pillar strategy built on Consumer Healthcare products, Generics, and Specialty Pharmaceuticals. In the OTC market, STADA and ALIUD are neck and neck with Bayer for market leadership, while the company continues to gain share in specialty pharmaceuticals through new biosimilars.

With over 20 years of experience in the pharmaceutical industry, Mihal brings deep expertise from leadership roles at Ipsen, Ratiopharm, Sandoz, Sanofi, Zentiva, and most recently Glenmark Pharmaceuticals, where he served as Vice President and Regional Business Head for the Asia-Pacific (APAC) region, based in Singapore.